> Disorders > Neoplastic Process > Rhabdomyosarcoma

Sarcoma →

Rhabdomyosarcoma

Q: What is the typical treatment for rhabdomyosarcoma?

Rhabdomyosarcoma typically requires an aggressive treatment regimen involving a combination of surgery, chemotherapy, and radiation therapy. Early diagnosis and appropriate management are crucial for improving patient outcomes. The specific treatment plan will depend on the subtype, location, and stage of the cancer.

Rhabdomyosarcoma is a highly malignant type of soft tissue sarcoma that arised from primitive mesenchymal cells.
It is the most common soft tissue sarcoma in children and adolescents, often occurring in the head, neck, genitourinary tract, and extremities.
Subtypes include embryonal, alveolar, and pleomorphic rhabdomyosarcoma.
Aggressive treatment with a combination of surgery, chemotherapy, and radiation therapy is typically required.
Early diagnosis and appropriate management are crucial for improving patient outcomes.
Researchers can utilize PubCompare.ai to optimize their rhabdomyosarcoma studies by easily accessing the best protocols, pre-prints, and patents, enhancing reproducibility and accuracy to drive breakthroughts.

Most cited protocols related to «Rhabdomyosarcoma»

Chemoresistant cancer cell line establishment

Cited 30 times

The N-myc-amplified neuroblastoma cell lines UKF-NB-2, UKF-NB-3, and UKF-NB-6 were established from stage 4 neuroblastoma patients.^{31 (link), 32 (link), 33 (link)} The alveolar rhabdomyosarcoma cell line UKF-Rhb-1 was established from a bone marrow metastasis.^{11 (link)} The melanoma cell lines Colo-679 and Mel-HO were obtained from the DSMZ (Braunschweig, Germany).
Parental chemosensitive cell lines were adapted to growth in the presence of anti-cancer drugs by continuous exposure of these cell lines to the increasing concentrations of these drugs as described before.^{31 (link), 32 (link)}The following chemoresistant UKF-NB-3 sublines were derived from the resistant cancer cell line (RCCL) collection: UKF-NB-3^rCDDP¹⁰⁰⁰ (adapted to CDDP), UKF-NB-3^rDAC⁸ (DAC), UKF-NB-3^rDOX²⁰ (DOX), UKF-NB-3^rGEMCI¹⁰ (GEMCI), UKF-NB-3^rIRINO⁸⁰⁰ (IRINO), UKF-NB-3^rMEL⁴⁰⁰ (MEL), UKF-NB-3^rOXALI²⁰⁰⁰ (OXALI), UKF-NB-3^rPCL²⁰ (PCL), UKF-NB-3^rTOPO¹⁵ (TOPO), UKF-NB-3^rVCR¹⁰ (VCR), and UKF-NB-3^rVINOR²⁰ (VINOR).
The following chemoresistant UKF-NB-2 sublines were derived from the RCCL collection: UKF-NB-2^rCDDP¹⁰⁰⁰, UKF-NB-2^rDOX²⁰, and UKF-NB-2^rVCR¹⁰.
The following chemoresistant UKF-Rhb-1 sublines were derived from the RCCL collection: UKF-Rhb-1^rCDDP¹⁰⁰⁰ and UKF-Rhb-1^rDOCE¹⁰ (DOCE), UKF-Rhb-1^rDOX¹⁰, UKF-Rhb-1^rGEMCI¹⁰, UKF-Rhb-1^rIRINO²⁰⁰, UKF-Rhb-1^rMEL⁴⁰⁰, UKF-Rhb-1^rOXALI¹⁰⁰⁰, and UKF-Rhb-1^rVCR¹⁰Moreover, the following melanoma sub-lines were derived from the RCCL collection: Colo-679^rVCR²⁰, Colo-679^rPLX4032^10 μM (PLX4032, vemurafenib), MelHO^rVCR²⁰, MelHO^rCDDP¹⁰⁰⁰, MelHO^rDAC²⁰, and MelHO^rPLX4032^10 μM.
The corresponding IC₅₀ values for the parental cells and their drug-resistant sublines are provided in Supplementary Table 4.
All cells were propagated in IMDM supplemented with 10% FBS, 100 IU/ml penicillin and 100 mg/ml streptomycin at 37 °C. Cells were routinely tested for mycoplasma contamination and authenticated by short tandem repeat profiling.
Standard molecular cloning techniques were used to generate lentiviral vectors based on Lentiviral Gene Ontology vector technology (see http://www.lentigo-vectors.de), and cell transduction was performed as described before.^{11 (link), 18 (link), 34 (link)}

Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M., Löschmann N., Voges Y., Breitling R., von Deimling A., Rödel F., Weber K., Fehse B., Mack E., Stiewe T., Doerr H.W., Speidel D, & Cinatl J j.r. (2011). Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. Cell Death & Disease, 2(12), e243-.

Publication 2011

Alveolar Epithelial Cells Alveolar Rhabdomyosarcoma Antineoplastic Agents Bone Marrow Cell Lines Cells Cisplatin Cloning Vectors Lentigo LINE-1 Elements Malignant Neoplasms Melanoma Mycoplasma Neoplasm Metastasis Neuroblastoma Parent Patients Penicillins Pharmaceutical Preparations PLX4032 Rhabdomyosarcoma Rhabdomyosarcoma 1 Short Tandem Repeat Streptomycin Topotecan Vemurafenib

Adolescent and Young Adult Cancer Study

Cited 11 times

Patients were identified through seven population-based Surveillance, Epidemiology and End-Results (SEER) program cancer registries: Detroit; Seattle/Puget Sound; Los Angeles County, San Francisco/Oakland, Greater California (13 counties around Sacramento plus Orange County), and the states of Iowa and Louisiana.
Conduct of this study required approval from 9 Institutional Review Boards (IRBs) (7 registries, 1 state (California) and the NCI IRB), which took 7 months. Several registries experienced particularly long approval processes because the inclusion of minors required changes to consent forms. No concerns were raised by the IRB about survey content, although there was concern about security of the online survey that was resolved with a more complete explanation of the security protocols. The online survey website included a firewall, Virtual Private Network (VPN), an intrusion detection system, and routine security checks of the computer resources. Patients were given a website address, user name and password in the initial mailing. Patients accessing the online survey were required to create a new password upon entering the system. This process made the survey accessible only to the person with the new password. Once the survey was submitted no further access was allowed.
Eligible patients were diagnosed between July 1, 2007 and October 31, 2008 with a first invasive, histologically confirmed germ cell cancer, non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), acute lymphocytic leukemia, Ewing’s sarcoma, osteosarcoma, or rhabdomyosarcoma (Appendix I), ages 15 through 39 years at diagnosis, residents of the study area and able to read English. The goal was to obtain 530 surveys completed 6–14 months from the date of diagnosis. A small sample of deceased patients who were otherwise eligible was included in the medical record review.

Harlan L.C., Lynch C.F., Keegan T.H., Hamilton A.S., Wu X.C., Kato I., West M.M., Cress R.D., Schwartz S.M., Smith A.W., Deapen D., Stringer S.M, & Potosky A.L. (2011). Recruitment and follow-up of adolescent and young adult cancer survivors: the AYA HOPE Study. Journal of Cancer Survivorship, 5(3), 305-314.

Publication 2011

Diagnosis Ewings Sarcoma Germ Cell Cancer Hodgkin Disease Lymphoma, Non-Hodgkin, Familial Malignant Neoplasms Osteosarcoma Patients Precursor Cell Lymphoblastic Leukemia Lymphoma Rhabdomyosarcoma Secure resin cement Sound

Gene Expression Analysis of Mouse and Human Tumors

Cited 9 times

Gene expression analysis was performed using Affymetrix Mouse 430A arrays (Affymetrix, Santa Clara, CA). Original CEL files of the mouse ARMS are uploaded in Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/). For human tumors, published data sets of rhabdomyosarcomas (8 (link), 9 (link)), juvenile and old skeletal muscles (10 (link)), Duchene muscular dystrophy (11 (link)) and a series of mesenchymal tumors (12 (link), 13 (link)) and pediatric malignancies (14 (link)) were used (Supplementary table S5). For mouse tumors, published datasets of osteosarcoma (15 (link)) and medulloblastoma (16 (link)) were utilized. Methods of microarray analysis including GSEA and metagene analysis are described in Supplementary Methods.

Nishijo K., Chen Q.R., Zhang L., McCleish A.T., Rodriguez A., Cho M.J., Prajapati S.I., Gelfond J.A., Chisholm G.B., Michalek J.E., Aronow B.J., Barr F.G., Randall R.L., Ladanyi M., Qualman S.J., Rubin B.P., LeGallo R.D., Wang C., Khan J, & Keller C. (2009). Credentialing a Preclinical Mouse Model of Alveolar Rhabdomyosarcoma. Cancer research, 69(7), 2902-2911.

Publication 2009

Arm, Upper Gene Expression Gene Expression Profiling Homo sapiens Malignant Neoplasms Medulloblastoma Mesenchyma Microarray Analysis Mus Muscular Dystrophy Neoplasms Osteosarcoma Rhabdomyosarcoma Skeletal Muscles

Establishment of Mouse and Human Rhabdomyosarcoma Cell Lines

Cited 8 times

Mouse embryonic fibroblasts (MEFs) deficient of p53, originally generated by Dr. D.J. Kwiatkowski at Harvard Medical School, were graciously provided by Dr. Samy L. Habib. For establishment of the mouse rhabdomyosarcoma cell lines, tumor samples were minced into small fragments followed by collagenase treatment (0.5%) overnight at 4°C. The dissociated cells were incubated in DMEM supplemented with 10% fetal bovine serum and penicillin (100 U/ml)/streptomycin (100μg/ml) (Invitrogen) in 5% CO₂ in air at 37°C. Human alveolar rhabdomyosarcoma cell lines (Rh5 and Rh30) were generously provided by the Houghton laboratory at St Jude’s Cancer Research Hospital. Human skeletal muscle cell line (SkMC) was obtained from Lonza (Basel, Switzerland).

Taniguchi E., Nishijo K., McCleish A.T., Michalek J.E., Grayson M.H., Infante A.J., Abboud H.E., Legallo R.D., Qualman S.J., Rubin B.P, & Keller C. (2008). PDGFR-A is a Therapeutic Target in Alveolar Rhabdomyosarcoma. Oncogene, 27(51), 6550.

Publication 2008

Alveolar Rhabdomyosarcoma Cell Lines Cells Collagenase Embryo Fetal Bovine Serum Fibroblasts Homo sapiens Mus Neoplasms Penicillins Rhabdomyosarcoma Skeletal Muscles Streptomycin

Murine and Human Cancer Cell Culture

Cited 8 times

Murine F9 teratocarcinoma (CRL-1720), human A673 rhabdomyosarcoma (CRL-1598) were from American Type Culture Collection (ATCC) and HUVE cells from PromoCell (Heidelberg, Germany). The cell culture media DMEM and HUVEC growth medium were from Gibco, Paisley, UK. Peritoneal macrophages were freshly isolated from Sv129 mice. Female Sv129 mice and CD1 nude mice were from Charles River Wiga (Sulzfeld, Germany) and kept in standard housing and normal diet at the animal facility of the Paul Scherrer Institute. Animal studies were approved by the Veterinary Department of the Canton Aargau, Switzerland and performed under the licenses (No. 75533 and 75534) issued to RA Schwendener. The ethical guidelines that were followed meet the standards required by the UKCCCR guidelines (Workman et al, 1998 ).

Zeisberger S.M., Odermatt B., Marty C., Zehnder-Fjällman A.H., Ballmer-Hofer K, & Schwendener R.A. (2006). Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. British Journal of Cancer, 95(3), 272-281.

Publication 2006

Animals Cell Culture Techniques Cells Culture Media Diet Females Homo sapiens Macrophages, Peritoneal Mice, Nude Mus Rhabdomyosarcoma Rivers Teratocarcinoma

Most recents protocols related to «Rhabdomyosarcoma»

Evaluating DMPK siRNA Potency in Cell Lines

Not available on PMC !

Example 17

To further validate the activity of the DMPK siRNAs, many of the sequences that showed the best activity in the initial screen were selected for a follow-up evaluation in dose response format. Once again, two human cell lines were used to assess the in vitro activity of the DMPK siRNAs: first, SJCRH30 human rhabdomyosarcoma cell line; and second, Myotonic Dystrophy Type 1 (DM1) patient-derived immortalized human skeletal myoblasts. The selected siRNAs were transfected in a 10-fold dose response at 100, 10, 1, 0.1, 0.01, 0,001, and 0.0001 nM final concentrations or in a 9-fold dose response at 50, 5.55556, 0.617284, 0.068587, 0.007621, 0.000847, and 0.000094 nM final concentrations. The siRNAs were formulated with transfection reagent Lipofectamine RNAiMAX (Life Technologies) according to the manufacturer's “forward transfection” instructions. Cells were plated 24 h prior to transfection in triplicate on 96-well tissue culture plates, with 8500 cells per well for SJCRH30 and 4000 cells per well for DM1 myoblasts. At 48 h (SJCRH30) or 72 h (DM1 myoblasts) post-transfection cells were washed with PBS and harvested with TRIzol® reagent (Life Technologies). RNA was isolated using the Direct-zol-96 RNA Kit (Zymo Research) according to the manufacturer's instructions. 10 μl of RNA was reverse transcribed to cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's instructions. cDNA samples were evaluated by qPCR with DMPK-specific and PPIB-specific TaqMan human gene expression probes (Thermo Fisher) using TaqMan® Fast Advanced Master Mix (Applied Biosystems). DMPK values were normalized within each sample to PPIB gene expression. The quantification of DMPK downregulation was performed using the standard 2^−ΔΔCta method. All experiments were performed in triplicate, with Tables 16A-B, 17A-B, and 18A-B presenting the mean values of the triplicates as well as the calculated IC₅₀values determined from fitting curves to the dose-response data by non-linear regression.

TABLE 16A

sense strandSEQantisense strandSEQ

sequence (5′-3′)IDsequence (5′-3′)ID

ID #¹Passenger Strand (PS)NO:Guide Strand (GS)NO:

535GGGCGAGGUGUCGUGCUUA9349UAAGCACGACACCUCGCCC12053

584GACCGGCGGUGGAUCACGA9398UCGUGAUCCACCGCCGGUC12102

716AUGGCGCGCUUCUACCUGA9530UCAGGUAGAAGCGCGCCAU12234

1028CAGACGCCCUUCUACGCGA9842UCGCGUAGAAGGGCGUCUG12546

1276UUUCGAAGGUGCCACCGAA10090UUCGGUGGCACCUUCGAAA12794

1825UGCUCCUGUUCGCCGUUGA10639UCAACGGCGAACAGGAGCA13343

1945CCCUAGAACUGUCUUCGAA10759UUCGAAGACAGUUCUAGGG13463

2529CUUCGGCGGUUUGGAUAUA11343UAUAUCCAAACCGCCGAAG14047

2558GUCCUCCGACUCGCUGACA11372UGUCAGCGAGUCGGAGGAC14076

2628CCGACAUUCCUCGGUAUUA11442UAAUACCGAGGAAUGUCGG14146

2636CCUCGGUAUUUAUUGUCUA11450UAGACAAUAAAUACCGAGG14154

¹19mer position in NM_001288766.1

TABLE 16B

IC50

ID #¹qPCR²qPCR³qPCR⁴qPCR⁵qPCR⁶qPCR⁷qPCR⁸(nM)

535111.9105.4106.382.436.729.535.70.165

58490.590.284.767.838.025.828.30.190

71688.985.281.962.032.619.320.30.181

102888.581.883.061.332.727.331.50.127

127687.085.084.066.140.534.036.40.150

182585.185.983.769.136.225.225.00.259

194585.081.774.444.922.917.717.20.070

252983.381.875.350.624.617.517.70.103

255884.381.174.345.423.413.311.80.088

262885.384.079.559.830.323.525.10.140

263686.386.974.344.019.812.413.00.070

²SJCRH30; 0.0001 nM; % DMPK mRNA

³SJCRH30; 0.001 nM; % DMPK mRNA

⁴SJCRH30; 0.01 nM; % DMPK mRNA

⁵SJCRH30; 0.1 nM; % DMPK mRNA

⁶SJCRH30; 1 nM; % DMPK mRNA

⁷SJCRH30; 10 nM; % DMPK mRNA

⁸SJCRH30; 100 nM; % DMPK mRNA

TABLE 17A

sense strandSEQantisense strandSEQ

sequence (5′-3′)IDsequence (5′-3′)ID

ID #¹Passenger Strand (PS)NO:Guide Strand (GS)NO:

2600CAAUCCACGUUUUGGAUGA11414UCAUCCAAAACGUGGAUUG14118

2636CCUCGGUAUUUAUUGUCUA11450UAGACAAUAAAUACCGAGG14154

2675CCCCGACCCUCGCGAAUAA11489UUAUUCGCGAGGGUCGGGG14193

2676CCCGACCCUCGCGAAUAAA11490UUUAUUCGCGAGGGUCGGG14194

2679GACCCUCGCGAAUAAAAGA11493UCUUUUAUUCGCGAGGGUC14197

2680ACCCUCGCGAAUAAAAGGA11494UCCUUUUAUUCGCGAGGGU14198

2681CCCUCGCGAAUAAAAGGCA11495UGCCUUUUAUUCGCGAGGG14199

2682CCUCGCGAAUAAAAGGCCA11496UGGCCUUUUAUUCGCGAGG14200

¹19mer position in NM_001288766.1

TABLE 17B

IC50

ID #¹qPCR²qPCR³qPCR⁴qPCR⁵qPCR⁶qPCR⁷(nM)

2600107.5107.6108.1106.3103.172.731.31

263681.181.174.047.225.711.50.073

267588.188.384.364.638.120.70.151

267688.978.984.472.744.935.60.204

267984.087.382.753.331.413.50.091

268087.485.385.168.544.539.60.110

268187.085.477.649.626.516.00.061

268282.483.977.150.827.331.10.047

²SJCRH30; 0.000094 nM; % DMPK mRNA

³SJCRH30; 0.000847 nM; % DMPK mRNA

⁴SJCRH30; 0.007621 nM; % DMPK mRNA

⁵SJCRH30; 0.068587 nM; % DMPK mRNA

⁶SJCRH30; 0.617284 nM; % DMPK mRNA

⁷SJCRH30; 5.55556 nM; % DMPK mRNA

TABLE 18A

sense strandSEQantisense strandSEQ

sequence (5′-3′)IDsequence (5′-3′)ID

ID #¹Passenger Strand (PS)NO:Guide Strand (GS)NO:

584GACCGGCGGUGGAUCACGA9398UCGUGAUCCACCGCCGGUC12102

716AUGGCGCGCUUCUACCUGA9530UCAGGUAGAAGCGCGCCAU12234

1265UUUACACCGGAUUUCGAAA10079UUUCGAAAUCCGGUGUAAA12783

1297AUGCAACUUCGACUUGGUA10111UACCAAGUCGAAGUUGCAU12815

1945CCCUAGAACUGUCUUCGAA10759UUCGAAGACAGUUCUAGGG13463

1960CGACUCCGGGGCCCCGUUA10774UAACGGGGCCCCGGAGUCG13478

2529CUUCGGCGGUUUGGAUAUA11343UAUAUCCAAACCGCCGAAG14047

2530UUCGGCGGUUUGGAUAUUA11344UAAUAUCCAAACCGCCGAA14048

2531UCGGCGGUUUGGAUAUUUA11345UAAAUAUCCAAACCGCCGA14049

2554CCUCGUCCUCCGACUCGCA11368UGCGAGUCGGAGGACGAGG14072

2628CCGACAUUCCUCGGUAUUA11442UAAUACCGAGGAAUGUCGG14146

2629CGACAUUCCUCGGUAUUUA11443UAAAUACCGAGGAAUGUCG14147

2681CCCUCGCGAAUAAAAGGCA11495UGCCUUUUAUUCGCGAGGG14199

¹19mer position in NM_001288766.1

TABLE 18B

IC50

ID #¹qPCR²qPCR³qPCR⁴qPCR⁵qPCR⁶qPCR⁷(nM)

58490.877.097.771.945.029.70.228

71696.582.577.064.643.333.90.080

126568.580.968.057.137.525.70.146

129771.467.269.453.540.525.40.171

194571.862.341.729.822.415.30.006

196063.065.462.145.831.128.30.068

252963.558.749.231.122.921.90.017

253069.366.753.143.238.824.50.016

253169.972.457.340.235.425.60.018

255468.270.151.243.032.117.30.043

262869.767.962.538.431.617.10.042

262972.165.669.042.134.413.70.078

268182.491.587.655.529.319.60.084

²DM1 myoblasts; 0.000094 nM; % DMPK mRNA

³DM1 myoblasts; 0.000847 nM; % DMPK mRNA

⁴DM1 myoblasts; 0.007621 nM; % DMPK mRNA

⁵DM1 myoblasts; 0.068587 nM; % DMPK mRNA

⁶DM1 myoblasts; 0.617284 nM; % DMPK mRNA

⁷DM1 myoblasts; 5.55556 nM; % DMPK mRNA

US11872287B2. Compositions and methods of treating muscle atrophy and myotonic dystrophy (2024-01-16). Avidity Biosciences, Inc. [US]. Inventors: Andrew John Geall [US], Venkata Doppalapudi [US], David Sai-Ho Chu [US], Michael Caramian Cochran [US], Michael Hood [US], Beatrice Diana Darimont [US], Rob Burke [US], Yunyu Shi [US], Gulin Erdogan Marelius [US], Barbora Malecova [US].

Patent 2024

Cell Lines Cells DNA, Complementary Down-Regulation Gene Expression Homo sapiens Lipofectamine Myoblasts Myoblasts, Skeletal Myotonic Dystrophy NM-107 Patients PPIB protein, human Reverse Transcription Rhabdomyosarcoma RNA, Messenger RNA, Small Interfering Tissues Transfection trizol

Cytotoxic Activity of Extracts

A standard cytotoxic activity test was performed [60 (link)] using the MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) assay [61 (link),62 ]. The following cell lines were used (cell lines were donated from the collection of cell lines of the Institute of Virology, Vaccines and Serums "Torlak", Belgrade, Serbia): RD (cell line derived from human rhabdomyosarcoma), Hep2c (cell line derived from human cervix carcinoma–HeLa derivative) and L2OB (cell line derived from murine fibroblast), against which the activity of the obtained extracts was measured. The results were expressed as IC₅₀ values (µg/mL), a threshold which was defined as the concentration of an agent inhibiting cell survival by 50% in comparison to a vehicle-treated control [63 (link)].

Mašković P.Z., Stagiopoulou R., Miletić N., Krigas N, & Lazari D. (2023). Ecological Preferences and Diversity of Essential Oil Composition in Endangered Wild-Growing Populations of Sideritis sipylea Boiss. (Lamiaceae) of the East Aegean Islands (Greece): Evidencing Antioxidant Potential, Antimicrobial and Cytotoxic Activities. Plants, 12(4), 836.

Publication 2023

Biological Assay Bromides Cell Lines Cell Survival Cervical Cancer diphenyl Fibroblasts HeLa Cells Homo sapiens Mus Rhabdomyosarcoma Serum Tetrazolium Salts Vaccines

Nationwide HFMD Pathogen Surveillance

To effectively monitor HFMD incidence, a national HFMD pathogen surveillance net was established in mainland China in 2008 for healthy individuals and HFMD patients [13 (link)]. The Shandong Center for Disease Control and Prevention collected their clinical samples during 2010–2011 for further identification at the National Polio Laboratory following strict compliance with the Polio Laboratory Manual (4th edition, 2004), published by the World Health Organization. Samples were inoculated in human rhabdomyosarcoma (RD) and human laryngeal epidermoid carcinoma (HEp-2) cell lines, respectively [14 (link)]. Cell cultures were collected after complete EV-like cytopathic effects were observed.
All patients or their guardians provided informed consent. The Ethics Review Committee of the National Institute for Viral Disease Control and Prevention (IVDC) of the Chinese Center for Disease Control and Prevention approved the study and confirmed that all methods were performed in accordance with standard guidelines.

Xiao J., Wang J., Lu H., Song Y., Sun D., Han Z., Li J., Yang Q., Yan D., Zhu S., Pei Y., Wang X., Xu W, & Zhang Y. (2023). Genomic Epidemiology and Transmission Dynamics of Global Coxsackievirus B4. Viruses, 15(2), 569.

Publication 2023

Cell Culture Techniques Cell Lines Chinese Cytopathogenic Effect, Viral Homo sapiens Laryngeal Squamous Cell Carcinoma Legal Guardians pathogenesis Patients Poliomyelitis Rhabdomyosarcoma Virus Diseases

Isolation and Characterization of CVA6 HFMD Virus

One CVA6 clinical isolate, F219, was isolated from a severe case during an outbreak of HFMD in Yunnan in 2016. In addition to the typical clinical manifestations of HFMD, such as fever, rash on hands and feet, this patient also presented some nervous system symptoms, such as headache, poor spirit, lethargy, etc.
Human rhabdomyosarcoma (RD; ATCC) cells were cultured in Dulbecco’s modified Eagle medium (DMEM) (Gibco, CA, USA) containing 10% fetal bovine serum (FBS) (Gibco, USA) and 1% penicillin-streptomycin (HyClone, Logan, UT, USA) at 37 °C with 5% CO₂. In addition, human glioma cells (U251; ATCC) were cultured in a 1:1 mixture of DMEM and F-12 (Gibco, California, USA), supplemented with 10% FBS. After the degree of cell fusion reached 80–90%, the medium was replaced with medium containing 2% FBS (maintenance media; MM) and incubated with the virus to obtain CPE. After three freeze-thaw cycles, all viruses in the supernatant were filtered through a 0.2-mm filter and stored at −80 °C.
All ICR mice were raised in independently ventilated cages and were provided with sufficient food and water.

Sun Q., Li J., Wang R., Sun T., Zong Y., Wang C., Liu Y., Li X., Song Y, & Zhang Y. (2023). Coxsackievirus A6 Infection Causes Neurogenic Pathogenesis in a Neonatal Murine Model. Viruses, 15(2), 511.

Publication 2023

Cells Eagle Exanthema Fetal Bovine Serum Fever Food Foot Freezing Fusions, Cell Glioma Headache Homo sapiens Lethargy Mice, Inbred ICR Neurologic Symptoms Patients Penicillins Rhabdomyosarcoma Streptomycin Virus

EV-A71 Antiviral Assay Protocol

The EV-A71 laboratory-adapted BrCr strain and clinical isolates representative of B genogroup (B2 subgenogroup: 11316; B5 subgenogroup: TW/70902/08) and C genogroup (C2 subgenogroup: H08300 461#812; C4 subgenogroup: TW/1956/05) were used at a low multiplicity of infection (MOI) in a standardized cell-based antiviral assay. Briefly, rhabdosarcoma (RD) cells were seeded in a 96-well plate. The day after, a serial dilution of the compounds and the virus inoculum were added to the cells. The assay plates were incubated at 37 °C, 5% CO₂ with virus inoculum and compounds until full virus-induced cell death was observed in the untreated, infected controls (3 days post-infection). Subsequently, the antiviral effect was quantified using a colorimetric readout with MTS/phenazine methosulfate (MTS/PMS method), and the compound concentration at which 50% inhibition of virus-induced cell death is observed (EC₅₀) was calculated from the antiviral dose–response curves. A similar assay setup was used to determine the adverse effect of the compound on uninfected, treated cells for calculation of the CC₅₀ (concentration of compound that reduces overall cell health by 50% as determined with the MTS/PMS method). The selectivity index (SI) was calculated as the ratio of CC₅₀ to EC₅₀.

Martí-Marí O., Abdelnabi R., Schols D., Neyts J., Camarasa M.J., Gago F, & San-Félix A. (2023). Insertion of an Amphipathic Linker in a Tetrapodal Tryptophan Derivative Leads to a Novel and Highly Potent Entry Inhibitor of Enterovirus A71 Clinical Isolates. International Journal of Molecular Sciences, 24(4), 3539.

Publication 2023

Antiviral Agents Biological Assay Cell Death Cells Colorimetry Enterovirus 71, Human fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether Genetic Selection Genogroup Infection Methylphenazonium Methosulfate Rhabdomyosarcoma Strains Technique, Dilution Virus

Top products related to «Rhabdomyosarcoma»

Fetal bovine serum (fbs) by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal

Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.

Dulbecco modified eagle medium (dmem) by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, France, Australia, Canada, Japan, Italy, Switzerland, Belgium, Austria, Spain, Israel, New Zealand, Ireland, Denmark, India, Poland, Sweden, Argentina, Netherlands, Brazil, Macao, Singapore, Sao Tome and Principe, Cameroon, Hong Kong, Portugal, Morocco, Hungary, Finland, Puerto Rico, Holy See (Vatican City State), Gabon, Bulgaria, Norway, Jamaica

DMEM (Dulbecco's Modified Eagle's Medium) is a cell culture medium formulated to support the growth and maintenance of a variety of cell types, including mammalian cells. It provides essential nutrients, amino acids, vitamins, and other components necessary for cell proliferation and survival in an in vitro environment.

Streptomycin by Thermo Fisher Scientific

Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama

Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.

Penicillin by Thermo Fisher Scientific

Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco

Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.

Ccl 136 by American Type Culture Collection

Sourced in United States, Germany

CCL-136 is a cell line derived from human embryonic kidney cells. It is a widely used tool in cell biology research and drug development. The core function of CCL-136 is to provide a standardized, renewable source of human kidney cells for in vitro experiments and assays.

Fetal bovine serum (fbs) by Merck Group

Sourced in United States, Germany, United Kingdom, Japan, Italy, China, Macao, Switzerland, France, Canada, Sao Tome and Principe, Spain, Australia, Ireland, Poland, Belgium, Denmark, India, Sweden, Israel, Austria, Brazil, Czechia, Netherlands, Portugal, Norway, Holy See (Vatican City State), New Zealand, Hungary, Senegal, Argentina, Thailand, Singapore, Ukraine, Mexico

FBS, or Fetal Bovine Serum, is a commonly used cell culture supplement. It is derived from the blood of bovine fetuses and provides essential growth factors, hormones, and other nutrients to support the growth and proliferation of a wide range of cell types in vitro.

L glutamine by Thermo Fisher Scientific

Sourced in United States, United Kingdom, Germany, France, Canada, Switzerland, Italy, Australia, Belgium, China, Japan, Austria, Spain, Brazil, Israel, Sweden, Ireland, Netherlands, Gabon, Macao, New Zealand, Holy See (Vatican City State), Portugal, Poland, Argentina, Colombia, India, Denmark, Singapore, Panama, Finland, Cameroon

L-glutamine is an amino acid that is commonly used as a dietary supplement and in cell culture media. It serves as a source of nitrogen and supports cellular growth and metabolism.

Penicillin streptomycin by Thermo Fisher Scientific

Sourced in United States, Germany, United Kingdom, China, Canada, France, Japan, Australia, Switzerland, Israel, Italy, Belgium, Austria, Spain, Gabon, Ireland, New Zealand, Sweden, Netherlands, Denmark, Brazil, Macao, India, Singapore, Poland, Argentina, Cameroon, Uruguay, Morocco, Panama, Colombia, Holy See (Vatican City State), Hungary, Norway, Portugal, Mexico, Thailand, Palestine, State of, Finland, Moldova, Republic of, Jamaica, Czechia

Penicillin/streptomycin is a commonly used antibiotic solution for cell culture applications. It contains a combination of penicillin and streptomycin, which are broad-spectrum antibiotics that inhibit the growth of both Gram-positive and Gram-negative bacteria.

Minimum essential medium (mem) by Thermo Fisher Scientific

Sourced in United States, United Kingdom, China, Germany, Japan, France, Italy, Belgium, Australia, Canada, Spain, Austria, Netherlands, Ireland, Argentina, Switzerland, Denmark, Morocco, Brazil, New Zealand, Moldova, Republic of, Poland

MEM is a cell culture medium designed for the growth and maintenance of a variety of cell types in vitro. It provides a balanced salt solution, amino acids, vitamins, and other essential nutrients required for cell proliferation and survival.

Cb17sc scid female mice by Taconic Biosciences

The CB17SC scid−/− female mice are a well-established immunodeficient mouse model. The scid mutation causes a severe combined immunodeficiency (SCID) phenotype, leading to the absence of functional T and B cells. This model is commonly used in research applications that require the engraftment of human cells or tissues.

What are the different subtypes of rhabdomyosarcoma?

The main subtypes of rhabdomyosarcoma include embryonal, alveolar, and pleomorphic. Embryonal rhabdomyosarcoma is the most common type, often occurring in the head, neck, genitourinary tract, and extremities of children. Alveolar rhabdomyosarcoma is more aggressive and typically found in older children and adolescents. Pleomorphic rhabdomyosarcoma is the rarest subtype and usually affects adults.

How can PubCompare.ai help with rhabdomyosarcoma research?

PubCompare.ai allows researchers to screen protocol literature more efficiently and leverage AI to pinpoint critical insights. The platform can help identify the most effective protocols related to rhabdomyosarcoma for your specific research goals. PubCompare.ai's AI-driven analysis can highlight key differences in protocol effectiveness, enabling you to choose the best option to enhance reproducibilty and accuracy, and drive breakthroughts.

What is the typical treatment for rhabdomyosarcoma?

What are some common challenges in using rhabdomyosarcoma research protocols?

One of the main challenges in using rhabdomyosarcoma research protocols is ensuring reproducibility and accuracy. With so many potential protocols available, it can be difficult to identify the most effective option for your specific research goals. PubCompare.ai can assist by leveraging AI to highlight key differences between protocols and help you choose the best one to drive your research forward with confidence.

How can PubCompare.ai help optimize rhabdomyosarcoma studies?

PubCompare.ai can help optimize rhabdomyosarcoma studies by allowing researchers to easly access the best protocols, pre-prints, and patents related to this type of soft tissue sarcoma. The platform's AI-driven comparisons can enhance reproducibilty and accuracy, empowering researchers to make informed decisions and drive breakthroughts. By leveraging PubCompare.ai, researchers can save time and effort in identifying the most effective approaches for their rhabdomyosacroma research.

More about "Rhabdomyosarcoma"

Rhabdomyosarcoma (RMS) is a highly aggressive type of soft tissue sarcoma that arises from primitive mesenchymal cells.
It is the most common soft tissue cancer in children and adolescents, often occurring in the head, neck, genitourinary tract, and extremities.
Subtypes include embryonal, alveolar, and pleomorphic RMS.
Effective treatment typically involves a combination of surgery, chemotherapy, and radiation therapy.
Early and accurate diagnosis is crucial for improving patient outcomes.
Researchers can utilize PubCompare.ai to optimize their RMS studies by easily accessing the best protocols, pre-prints, and patents, enhancing reproducibility and accuracy to drive breakthrougts.
The cell culture media DMEM and MEM, as well as the antibiotics Streptomycin and Penicillin, are commonly used in RMS research.
The CB17SC scid−/− female mouse model is also frequently employed.
L-glutamine is an important nutrient for cell growth.
Proper use of these materials and models is essential for advancing RMS research and developing new therapies.